Safety of baclofen versus tizanidine for older adults with musculoskeletal pain
Journal of the American Geriatrics Society · 2023
DOI: 10.1111/jgs.18349 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Geriatrics Society, 2023. Verfasst von Vanessa R Su Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ambulatory Care Pharmacy, Kaiser Permanente, San Rafael, California, USA. Hauptthemen laut MEDLINE: Muscle Relaxants, Central, Musculoskeletal Pain, Delirium. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background
Baclofen and tizanidine are both muscle relaxants that carry the risk for neuropsychiatric events in older adults but there is a lack of data directly comparing their safety. This study aimed to investigate the relative risk between these two medications in causing injury and delirium in older adults.
Methods
This was a retrospective cohort study that was completed in an integrated healthcare system in the United States and included patients aged 65 years or older who started baclofen or tizanidine for the treatment of musculoskeletal pain from January 2016 through December 2018. Outcomes included new incidence of injury (concussion, contusion, dislocation, fall, fracture, or other injuries) and delirium. The cohort was followed from the initiation of therapy until the first occurrence of any of the following events: end of the index drug exposure, end of health plan membership, death, or the study end date of December 31st, 2019. Descriptive statistics were used to compare baseline patient characteristics between baclofen and tizanidine treatment groups. Cox proportional hazards model was used to calculate adjusted hazard ratios (HRs) with 95% confidence intervals.
Results
The final study cohort included 12,101 and 6,027 older adults in the baclofen and tizanidine group respectively (mean age 72.2 ± 6.2 years old, 59% female). Older adults newly started on baclofen had a greater risk of injury (HR = 1.54, 95% CI = 1.21–1.96, P = < 0.001) and delirium (HR = 3.33, 95% CI = 2.11–5.26, p =
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ambulatory Care Pharmacy, Kaiser Permanente, San Rafael, California, USA.
- Pharmacy Outcomes Research Group, Kaiser Permanente, Downey, California, USA.
- Department of Internal Medicine, Southern California Permanente Medical Group, West Los Angeles, California, USA.
- Department of Neurology, Southern California Permanente Medical Group, Harbor City, California, USA.
- Department of Research & Evaluation, Southern California Permanente Medical Group, Pasadena, California, USA.
- Department of Family Medicine, Southern California Permanente Medical Group, Panorama City, California, USA.
ORCID-Profile: Benjamin I Broder, Rita L Hui
Zitieren
APA
Su Zhang, V. R., Niu, F., Lee, E. A., DiStasio, C., Broder, B. I., Steinberg, S. G., & Hui, R. L. (2023). Safety of baclofen versus tizanidine for older adults with musculoskeletal pain. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.18349
Vancouver
Su Zhang VR, Niu F, Lee EA, DiStasio C, Broder BI, Steinberg SG, et al. Safety of baclofen versus tizanidine for older adults with musculoskeletal pain. Journal of the American Geriatrics Society. 2023. doi:10.1111/jgs.18349
BibTeX
@article{SuZhang2023,
author = {Su Zhang, Vanessa R and Niu, Fang and Lee, Eric A and DiStasio, Christopher and Broder, Benjamin I and Steinberg, Steven G and Hui, Rita L},
title = {Safety of baclofen versus tizanidine for older adults with musculoskeletal pain},
journal = {Journal of the American Geriatrics Society},
year = {2023},
doi = {10.1111/jgs.18349}
}
EUVIMED